Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Celyad Oncology's Enterprise Value for the quarter that ended in Dec. 2025 was $4.71 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Celyad Oncology's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $1.11 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celyad Oncology EV-to-EBIT Related Terms
Celyad Oncology EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Celyad Oncology's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Celyad Oncology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celyad Oncology EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Celyad Oncology's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Celyad Oncology's EV-to-EBIT falls into.
Celyad Oncology's current Enterprise Value is $11.31 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Celyad Oncology's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $1.11 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celyad Oncology (CLYYF) has a EV-to-EBIT of 10.18 as of Jul. 18, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Celyad Oncology and its competitors. According to the industry distribution chart, Celyad Oncology ranks #167 out of 372 companies in the Biotechnology industry, placing it in the top 44.9%.
Is Celyad Oncology's EV-to-EBIT too high?
Celyad Oncology's current EV-to-EBIT is 10.18. The Biotechnology industry median EV-to-EBIT is 13.35. Celyad Oncology's value of 10.18 is 23.7% below this industry median. Based on the distribution chart, Celyad Oncology ranks #167 out of 372 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Celyad Oncology has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celyad Oncology's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Celyad Oncology ranks #167 out of 372 companies for EV-to-EBIT. This puts Celyad Oncology in the upper half of its industry. The industry median EV-to-EBIT is 13.35. Celyad Oncology's value of 10.18 is 23.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 13.35, based on 372 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celyad Oncology's current EV-to-EBIT of 10.18 is 23.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Celyad Oncology and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 13.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celyad Oncology's current EV-to-EBIT is 10.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celyad Oncology stock overvalued right now?
Based on GuruFocus' analysis, Celyad Oncology (CLYYF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $0.20 — trading 33.3% above its estimated fair value. The current EV-to-EBIT is 10.18 and 23.7% below the Biotechnology industry median of 13.35. Celyad Oncology's overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Celyad Oncology (CLYYF), the current EV-to-EBIT is 10.18 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celyad Oncology (CLYYF) Overvalued in 2026?
Based on GuruFocus' analysis, Celyad Oncology stock appears to be overvalued.
The current stock price of $0.20 is trading 33.3% above its estimated GF Value™ of $0.15.
GuruFocus considers Celyad Oncology to be Significantly Overvalued.
Key valuation signals for CLYYF:
EV-to-EBIT: 10.18
GF Value™: $0.15 vs. price of $0.20 (33.3% above fair value)
Industry Position: 23.7% below the Biotechnology median (#167 of 372)
No single metric tells the full story. See the CLYYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
28GF Score
Get the complete analysis for CLYYF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLYYF has been successfully added to your 
